Browse by Phase
Phase 1 / Phase 2 Clinical Trials
Phase 1/2 combined trials evaluate both safety (Phase 1) and preliminary efficacy (Phase 2) in a single study protocol, often used to accelerate early development.
Total Trials
401
Recruiting Now
401
Top Conditions in Phase 1 / Phase 2
Frequently Asked Questions — Phase 1 / Phase 2 Trials
What are combined Phase 1/2 clinical trials?
Phase 1/2 trials are adaptive designs that evaluate both safety (Phase 1 objectives) and preliminary efficacy (Phase 2 objectives) within a single trial protocol. They are commonly used in oncology and rare disease research to accelerate development timelines. Dose escalation occurs in the Phase 1 portion, followed by expansion cohorts at the selected dose in the Phase 2 portion.
Why do sponsors combine Phase 1 and Phase 2?
Combining phases reduces development time and cost, particularly for conditions with high unmet need. For rare diseases or cancer indications, finding sufficient eligible patients can be challenging—a combined design uses the same patient pool more efficiently. Regulatory agencies including the FDA encourage adaptive designs to accelerate evidence generation for serious conditions.
How do I find Phase 1/2 trials I can join?
Phase 1/2 trials listed on ClinicalMetric are sourced from ClinicalTrials.gov and filtered by recruitment status. Each listing shows enrollment status, conditions studied, sponsor, participating sites, and estimated enrollment. Because Phase 1/2 trials often have narrow eligibility criteria, carefully review the protocol and discuss potential participation with your treating physician.
Active Phase 1 / Phase 2 Studies
NCT05445154 Phase 1, Phase 2
Recruiting
SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed...
Condition
Newly Diagnosed Acute Myeloid Leukemia (AML)
Enrollment
58 pts
Location
China
Sponsor
CSPC ZhongQi Pharmaceutical Te
NCT05858983 Phase 1, Phase 2
Recruiting
Gene Therapy in Subjects With Biallelic RPE65 Mutation-associated Retinal Dystro...
Condition
Biallelic RPE65 Mutation-associated Retinal Dystrophy
Enrollment
9 pts
Location
China
Sponsor
Frontera Therapeutics
NCT06726161 Phase 1, Phase 2
Recruiting
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Id...
Condition
Hepatocellular Carcinoma (HCC)
Enrollment
590 pts
Location
United States
Sponsor
RayzeBio, Inc.
NCT06090266 Phase 1, Phase 2
Recruiting
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combinati...
Condition
Cancer
Enrollment
168 pts
Location
United States
Sponsor
OncoResponse, Inc.
NCT06030622 Phase 1, Phase 2
Recruiting
Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic C...
Condition
Pancreatic Cancer Metastatic
Enrollment
25 pts
Location
United States
Sponsor
State University of New York -
NCT06836856 Phase 1, Phase 2
Recruiting
Evaluating the Impact of Adjuvant Use of Beta Blockers on Clinical Outcomes in P...
Condition
TBI Traumatic Brain Injury
Enrollment
100 pts
Location
Egypt
Sponsor
Mansoura University
NCT06772623 Phase 1, Phase 2
Recruiting
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab ...
Condition
Non Small Cell Lung Carcinoma
Enrollment
252 pts
Location
United States, Argentina, Australia
Sponsor
AbbVie
NCT07577661 Phase 1, Phase 2
Recruiting
Combination Upper-Airway Electrical and Pharmacological Stimulation for Obstruct...
Condition
Obstructive Sleep Apnea
Enrollment
24 pts
Location
United States
Sponsor
Brigham and Women's Hospital
NCT02881970 Phase 1, Phase 2
Recruiting
Neonatal Hypoxic Ischemic Encephalopathy : Safety and Feasibility Study of a Cur...
Condition
Neonatal Hypoxic-ischaemic Encephalopathy
Enrollment
20 pts
Location
France
Sponsor
Assistance Publique Hopitaux D
NCT02259556 Phase 1, Phase 2
Recruiting
CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refra...
Condition
Hodgkin's Lymphoma
Enrollment
30 pts
Location
China
Sponsor
Chinese PLA General Hospital
NCT07631325 Phase 1, Phase 2
Recruiting
Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma
Condition
Unresectable Cutaneous Melanoma
Enrollment
28 pts
Location
United States
Sponsor
John Kirkwood
NCT05991583 Phase 1, Phase 2
Recruiting
A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Maligna...
Condition
Advanced Malignant Tumors
Enrollment
25 pts
Location
China
Sponsor
SUNHO（China）BioPharmaceutical
NCT07206056 Phase 1, Phase 2
Recruiting
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tul...
Condition
Progressive Metastatic Castrate Resistant Prostate Cancer
Enrollment
188 pts
Location
United States, Australia, Canada
Sponsor
Novartis Pharmaceuticals
NCT06977737 Phase 1, Phase 2
Recruiting
A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours
Condition
Solid Tumor, Adult
Enrollment
72 pts
Location
Spain, United Kingdom
Sponsor
Accession Therapeutics Limited
NCT05351593 Phase 1, Phase 2
Recruiting
Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
Condition
CNS Lymphoma
Enrollment
35 pts
Location
United States
Sponsor
James Rubenstein
NCT06848699 Phase 1, Phase 2
Recruiting
A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab i...
Condition
Solid Tumor Cancer
Enrollment
105 pts
Location
China
Sponsor
Shanghai Henlius Biotech
NCT06750185 Phase 1, Phase 2
Recruiting
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for A...
Condition
Advanced Solid Tumor
Enrollment
248 pts
Location
United States, Australia
Sponsor
BioNTech SE
NCT07105215 Phase 1, Phase 2
Recruiting
A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the ...
Condition
Solid Tumors
Enrollment
312 pts
Location
China
Sponsor
RemeGen Co., Ltd.
NCT05599048 Phase 1, Phase 2
Recruiting
Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors
Condition
Advanced Solid Tumor
Enrollment
65 pts
Location
United States
Sponsor
Robert Bok, MD, PhD
NCT05913752 Phase 1, Phase 2
Recruiting
A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Sub...
Condition
Alcohol Use Disorder
Enrollment
84 pts
Location
United States, Israel
Sponsor
Clearmind Medicine Inc.
NCT07295847 Phase 1, Phase 2
Recruiting
A Study of AZD0120 in Autoimmune Diseases
Condition
Systemic Sclerosis
Enrollment
27 pts
Location
United States, Australia, Germany
Sponsor
AstraZeneca
NCT06634108 Phase 1, Phase 2
Recruiting
Genistein in trAnSthyretin recePtor Amyloid caRdiomyopathy
Condition
Amyloid Cardiomyopathy
Enrollment
20 pts
Location
Canada
Sponsor
London Health Sciences Centre
NCT06189963 Phase 1, Phase 2
Recruiting
Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease
Condition
Moderate Alzheimer Disease
Enrollment
36 pts
Location
United States, Canada
Sponsor
NKGen Biotech, Inc.
NCT07891104 Phase 1, Phase 2
Recruiting
A Phase I/II Clinical Trial of the Diphtheria, Tetanus, Acellular Component Pert...
Condition
Diphtheria
Enrollment
380 pts
Location
China
Sponsor
Institute of Medical Biology,
NCT05684965 Phase 1, Phase 2
Recruiting
XTX301 in Patients With Advanced Solid Tumors
Condition
Advanced Solid Tumor
Enrollment
358 pts
Location
United States
Sponsor
Xilio Development, Inc.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology